Elevation Oncology (ELEV) Competitors

Immix Biopharma (NASDAQ:IMMX) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Which has more risk and volatility, IMMX or ELEV?

Immix Biopharma has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Which has better earnings and valuation, IMMX or ELEV?

Immix Biopharma is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$15.43M	-$0.70	-3.56
Elevation Oncology	N/A	N/A	-$45.70M	-$0.82	-0.46

Does the MarketBeat Community prefer IMMX or ELEV?

Elevation Oncology received 27 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 61.90% of users gave Elevation Oncology an outperform vote.

Company	Underperform	Outperform
Immix Biopharma	Outperform Votes 12 100.00%	Underperform Votes No Votes
Elevation Oncology	Outperform Votes 39 61.90%	Underperform Votes 24 38.10%

Do insiders & institutionals believe in IMMX or ELEV?

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 55.4% of Immix Biopharma shares are held by company insiders. Comparatively, 8.1% of Elevation Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Do analysts prefer IMMX or ELEV?

Immix Biopharma presently has a consensus target price of $7.00, indicating a potential upside of 181.12%. Elevation Oncology has a consensus target price of $3.39, indicating a potential upside of 790.51%. Given Elevation Oncology's higher possible upside, analysts plainly believe Elevation Oncology is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Elevation Oncology	0 Sell rating(s)	11 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is IMMX or ELEV more profitable?

Elevation Oncology's return on equity of -59.73% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-102.68%	-80.89%
Elevation Oncology	N/A	-59.73%	-40.05%

Does the media refer more to IMMX or ELEV?

In the previous week, Elevation Oncology had 16 more articles in the media than Immix Biopharma. MarketBeat recorded 28 mentions for Elevation Oncology and 12 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.74 beat Elevation Oncology's score of -0.05 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elevation Oncology	0 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Elevation Oncology beats Immix Biopharma on 8 of the 15 factors compared between the two stocks.